1 / 17

Neoadjuvant trials: Study designs

Epirubicin + cyclophosphamide + trastuzumab or lapatinib. Trastuzumab (1 year total therapy). Docetaxel + trastuzumab or lapatinib. GeparQuinto (P hase III). Neoadjuvant trials: Study designs. Neoadjuvant therapy. Adjuvant therapy. S U R G E R Y. FEC (3 cycles).

caldwell-porter
Download Presentation

Neoadjuvant trials: Study designs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Epirubicin +cyclophosphamide + trastuzumab or lapatinib Trastuzumab(1 year total therapy) Docetaxel + trastuzumab or lapatinib GeparQuinto (Phase III) Neoadjuvant trials: Study designs Neoadjuvant therapy Adjuvant therapy S U R G E R Y FEC (3 cycles) Trastuzumab (to complete 1 year) Trastuzumaband/orpertuzumab+/- docetaxel NeoSphere(Phase II) Trastuzumab + FEC (3 cycles) (to complete 1 year) Docetaxel* (4 cycles) Laptinib and / or trast-uzumab Paclitaxel+ lapatinib and/or trastuzumab Lapatinib and / or trastuzumab (34 weeks) FEC (3 cycles) NeoALTTO(Phase III) 0 -24 12 21 52 70 -18 -12 Weeks FEC, 5-fluorouracil + epirubicin + cyclophosphamide*Docetaxel only given to patients receiving chemotherapy-free neoadjuvant therapy • www.clinicaltrials.gov

  2. Neoadjuvant treatment regimens • www.clinicaltrials.gov

  3. S U R G E R Y S U R G E R Y L 6 weeks  L + PAC12 weeks FEC q3w x 3 → L 34 weeks E + C +H q3w x 4 T + H q3w x 4 H q3w 6 months H 6 weeks  H + PAC12 weeks FEC q3w x 3 → H 34 weeks NeoALTTO study design2 n=455 GeparQuinto study design1 n=615 E + C q3w x 4+ L 1250 mg qd T q3w x 4+ L 1250 mg qd H q3w 1 year L + H 6 weeks  L + H + PAC12 weeks FEC q3w x 3 → L + H 34 weeks Comparison of neoadjuvant studies: Mono HER2-targeted therapy FEC, 5-fluorouracil, epirubicin and cyclophosphamide H, trastuzumab; P, pertuzumab; T, docetaxel; L, lapatinib; PAC, paclitaxel • 1. Untch et al. SABCS 2010; Presentation S3-1 • 2. Baselga et al. SABCS 2010; Presentation S3-3

  4. GeparQuinto: Safety summary EC, epirubicin+cyclophosphamide; D, docetaxel; L, lapatinib, T, trastuzumab*Expressed as a percentage of N=310 • Untch et al. SABCS 2010; Presentation S3-1

  5. p<0.05 60 50 40 30 20 10 50.4 35.2 0 H+Ct L+Ct n = 307 308 GeparQuinto: pCR rate Patients achieving pCR (%) pCR defined as no invasive residual in breast based on central pathology report review; CI, confidence interval; Ct, chemotherapy; pCR, pathological complete response; H, trastuzumab; L, lapatinib; P, pertuzumab; T, docetaxel Untch et al. SABCS 2010; Presentation S3-1

  6. NeoALTTO: Safety summary *Includes 3 patients with Hy’s Law criteria (2 patients treated with trastuzumab and 1 patient treated with lapatinib) L, lapatinib, T, trastuzumab Baselga et al. SABCS 2010; Presentation S3-3

  7. GeparQuinto1 p<0.05 60 60 50 50 p=0.34 40 40 30 30 Patients achieving pCR (%) 20 20 10 10 50.4 35.2 0 0 H+Ct L+Ct H+Ct L+Ct n = 149 154 n = 307 308 Comparison of neoadjuvant studies: Mono HER2-targeted therapy NeoALTTO2 Patients achieving pCR (%) 29.5 24.7 For GeparQuinto pCR defined as no invasive residual in breast based on central pathology report review;for NeoALTTO pCR defined as no invasive cancer in the breast or only non-invasive in situ cancer in the breast specimen CI, confidence interval; Ct, chemotherapy; pCR, pathological complete response; H, trastuzumab; L, lapatinib; P, pertuzumab; T, docetaxel 1. Untch et al. SABCS 2010; Presentation S3-1 2. Baselga et al. SABCS 2010; Presentation S3-3

  8. NeoSphere: randomised Phase II study of neoadjuvant trastuzumab and pertuzumab TH (n=107) Trastuzumab + docetaxel FEC q3w x 3 Trastuzumab q3w cycles 5–17 S U R G E R Y Patients with operable or locally advanced /inflammatory* HER2-positive breast cancer Chemo-naïve & primary tumours >2cm (N=417) THP (n=107) Trastuzumab + docetaxel +pertuzumab FEC q3w x 3Trastuzumab q3w cycles 5–17 HP (n=107) Trastuzumab + pertuzumab Docetaxel q3w x 4→FEC q3w x 3 Trastuzumab q3w cycles 5–17 TP (n=96) Pertuzumab + docetaxel FEC q3w x 3 Trastuzumab q3w cycles 5–21 Study dosing: q3w x 4 *Locally advanced=T2–3, N2–3, M0 or T4a–c, any N, M0; operable=T2–3, N0–1, M0; inflammatory=T4d, any N, M0FEC, 5-fluorouracil, epirubicin and cyclophosphamide • Gianni et al. SABCS 2010; Presentation S3-2

  9. NeoSphere: pCR rate in ITT population p=0.0198 p=0.0141 p=0.003 60 50 40 30 Patients achieving pCR (% ± 95% CI) 20 10 45.8 16.8 24.0 29.0 0 TH THP HP TP pCR in the breast ITT, intent-to-treat; H, trastuzumab; P, pertuzumab; pCR, pathological complete response; T, docetaxel Gianni et al. SABCS 2010; Presentation S3-2

  10. NeoSphere: 10 most common grade ≥3 adverse events ALT, alanine animotransferase; LVEF, left ventricular ejection fraction H, trastuzumab; P, pertuzumab; T, docetaxel Gianni et al. SABCS 2010; Presentation S3-2

  11. Comparison of neoadjuvant studies: Combination HER2-targeted therapy Adjuvant treatment Neoadjuvant treatment S U R G E R Y TH (n=107) q3w x 4 FEC q3w x 3 H q3w cycles 5–17 THP (n=107) q3w x 4 FEC q3w x 3 H q3w cycles 5–17 NeoSphere study design1 n=417 HP (n=107) q3w x 4 T q3w x 4 → FEC q3w x 3 H q3w cycles 5–17 TP (n=96) q3w x 4 FEC q3w x 3 H q3w cycles 5–21 L 6 weeks  L + PAC 12 weeks S U R G E R Y FEC q3w x 3 → L 34 weeks NeoALTTO study design2 n=455 H 6 weeks  H + PAC 12 weeks FEC q3w x 3 → H 34 weeks L + H 6 weeks  L + H + PAC 12 weeks FEC q3w x 3 → L + H 34 weeks 1. Gianni et al. SABCS 2010; Presentation S3-22. Baselga et al. SABCS 2010; Presentation S3-3 FEC, 5-fluorouracil, epirubicin and cyclophosphamide; H, trastuzumab; P, pertuzumab; T, docetaxel; L, lapatinib; PAC, paclitaxel

  12. NeoSphere1 NeoALTTO2 60 60 50 50 40 40 30 30 20 20 10 10 0 0 TH THP H+Ct HL+Ct n = 107 107 n = 149 152 Comparison of neoadjuvant studies: Combination HER2-targeted therapy pCR rates* p=0.0141 p=0.0001 Patients achieving pCR(%) Patients achieving pCR (% ± 95% CI) 29.0 45.8 29.5 51.3 * For NeoSphere pCR in the breast; for NeoALTTO pCR defined as no invasive cancer in the breast or only non-invasive in situ cancer in the breast specimen CI, confidence interval; Ct, chemotherapy; pCR, pathological complete response; H, trastuzumab; L, lapatinib; P, pertuzumab; T, docetaxel 1. Gianni et al. SABCS 2010; Presentation S3-2 2. Baselga et al. SABCS 2010; Presentation S3-3

  13. Comparison of NeoSphere and NeoALTTO: safety • 1. Gianni et al. SABCS 2010; Presentation S3-2 • 2. Baselga et al. SABCS 2010; Presentation S3-3 Ct, chemotherapy; H, trastuzumab; L, lapatinib; P, pertuzumab; T, docetaxel

  14. Comparison of GeparQuinto and NeoALTTO: pCR* rates GeparQuinto1 NeoALTTO2 p=0.0001 p<0.05 p=0.34 60 60 50 50 40 40 Patients achieving pCR (%) Patients achieving pCR (%) 30 30 20 20 10 10 35.2 24.7 51.3 50.4 29.5 0 0 H+Ct L+Ct H+Ct L+Ct HL+Ct 307 308 n = 149 154 n = 152 * For GeparQuinto pCR defined as no invasive residual in breast based on central pathology report review; for NeoALTTO pCR defined as no invasive cancer in the breast or only non-invasive in situ cancer in the breast specimen 1. Untch et al. SABCS 2010; Presentation S3-1 2. Baselga et al. SABCS 2010; Presentation S3-3 CI, confidence interval; Ct, chemotherapy; pCR, pathological complete response; H, trastuzumab; L, lapatinib; P, pertuzumab; T, docetaxel

  15. Comparison of NeoSphere and NeoALTTO: pCR* rates NeoSphere 1 NeoALTTO2 p=0.0198 p=0.0001 p=0.003 p=0.0141 p=0.34 60 60 50 50 40 40 Patients achieving pCR (%) 30 Patients achieving pCR (% ± 95% CI) 30 20 20 10 10 24.7 51.3 45.8 16.8 24.0 29.5 29.0 0 0 H+Ct L+Ct HL+Ct TH THP HP TP 149 154 152 107 107 107 96 n = n = * For NeoSphere pCR in the breast; for NeoALTTO pCR defined as no invasive cancer in the breast or only non-invasive in situ cancer in the breast specimen 1. Gianni et al. SABCS 2010; Presentation S3-2 2. Baselga et al. SABCS 2010; Presentation S3-3 CI, confidence interval; Ct, chemotherapy; pCR, pathological complete response; H, trastuzumab; L, lapatinib; P, pertuzumab; T, docetaxel

  16. Comparison of NeoSphere and NeoALTTO: pCR* rates NeoSphere 1 NeoALTTO2 p=0.0198 p=0.0001 p=0.003 p=0.0141 p=0.34 60 60 50 50 40 40 Patients achieving pCR (%) 30 Patients achieving pCR (% ± 95% CI) 30 20 20 10 10 24.7 51.3 45.8 16.8 24.0 29.5 29.0 0 0 H+Ct L+Ct HL+Ct TH THP HP TP 149 154 152 107 107 107 96 n = n = * For NeoSphere pCR in the breast; for NeoALTTO pCR defined as no invasive cancer in the breast or only non-invasive in situ cancer in the breast specimen 1. Gianni et al. SABCS 2010; Presentation S3-2 2. Baselga et al. SABCS 2010; Presentation S3-3 CI, confidence interval; Ct, chemotherapy; pCR, pathological complete response; H, trastuzumab; L, lapatinib; P, pertuzumab; T, docetaxel

  17. GeparQuinto1 NeoSphere2 p=0.0198 p<0.05 p=0.003 p=0.0141 60 60 50 50 40 40 Patients achieving pCR (% ± 95% CI) Patients achieving pCR (%) 30 30 20 20 10 10 35.2 50.4 45.8 16.8 24.0 29.0 0 0 H+Ct L+Ct TH THP HP TP 307 308 107 107 107 96 n = Comparison of GeparQuinto, NeoSphere and NeoALTTO: pCR* rates NeoALTTO3 p=0.0001 p=0.34 60 50 40 Patients achieving pCR (%) 30 20 10 24.7 51.3 29.5 0 H+Ct L+Ct HL+Ct 154 152 149 n = n = * For GeparQuinto pCR defined as no invasive residual in breast based on central pathology report review; for NeoSphere pCR in the breast; for NeoALTTO pCR defined as no invasive cancer in the breast or only non-invasive in situ cancer in the breast specimen 1. Untch et al. SABCS 2010; Presentation S3-12. Gianni et al. SABCS 2010; Presentation S3-2 3. Baselga et al. SABCS 2010; Presentation S3-3 CI, confidence interval; Ct, chemotherapy; pCR, pathological complete response; H, trastuzumab; L, lapatinib; P, pertuzumab; T, docetaxel

More Related